Login to Your Account


FDA advisory committee grapples with egg cell modification’s scientific side

By Anette Breindl
Science Editor

Thursday, February 27, 2014
As an FDA advisory committee met over the past two days to discuss what it would take for clinical trials of “oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial disease or treatment of infertility” to go forward, the committee was trying walk the line between sticking to their part of the issue – the science that would inform such trials – and acknowledging that the science was not the only, and not even the most important, issue about whether such trials would be a good idea.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription